Bayer to partner with Twist Bioscience to accelerate drug discovery

Berlin, October 5, 2src23 – Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform.The company’s “Library of Libraries”, a collection of synthetic antibody libraries that harness innovative structural and developability features to cover a wide range of antibody drug targets…
Read More